Check Credit Score
Check Credit Score
HomeNewsIndia

Jubilant Life Sciences presents 1,000 vials of Remdesivir to Uttar Pradesh CM Yogi Adityanath

The drug is being made available to over 1,000 hospitals providing COVID-19 treatment in India through the company's distribution network, Jubilant Life Sciences said in a statement.

August 08, 2020 / 07:49 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Jubilant Life Sciences on Saturday said it has presented 1,000 vials of antiviral drug Remdesivir that it sells under the brand name 'JUBI-R' to Uttar Pradesh Chief Minister Yogi Adityanath.

The drug is being made available to over 1,000 hospitals providing COVID-19 treatment in India through the company's distribution network, Jubilant Life Sciences said in a statement.

"Remdesivir is an effective medicine in the treatment of severe COVID-19 cases. In this critical situation, I am pleased that this medicine was made available by Jubilant in the quick time of two and a half months," the company quoted Adityanath as saying.

"It gives us immense pleasure and satisfaction to present ‘JUBI-R', the life-saving medicine, to Chief Minister of Uttar Pradesh Yogi Adityanath," Jubilant Life Sciences Chairman Shyam S Bhartia said.

The company is donating 1000 vials of JUBI-R through its CSR arm, the Jubilant Bhartia Foundation, he added.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

In May 2020, Jubilant entered into a non-exclusive licensing agreement with Gilead Sciences, Inc., that granted it the right to register, manufacture and sell Gilead's investigational drug remdesivir in 127 countries including India, the company said.

Follow our full coverage of the coronavirus pandemic here.

PTI

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347